Newsfile Corp
13 Sept 2026, 08:56 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA issued a second Complete Response Letter (CRL) for Unicycive's kidney disease therapy, oxylanthanum, citing repeated third-party manufacturing deficiencies. — A second CRL for the same issues indicates a failure to remediate problems, significantly delaying or jeopardizing regulatory approval for a key product.
-0.80A federal securities class action lawsuit has been filed alleging Unicycive executives made false or misleading statements regarding their manufacturing vendor's FDA compliance. — Securities litigation creates legal liabilities and suggests potential governance failures, which typically weigh on stock valuation.
-0.50Unicycive's stock price experienced a single-day drop of 39.1% on June 30, 2026, following the FDA disclosure. — This confirms a high level of market volatility and a significant loss of investor confidence in the company's near-term prospects.
-0.30Which stocks this story touches
Continue reading
5 related stories
Search tags
The company is facing a securities class action lawsuit following a significant stock price drop and FDA rejection of its drug application.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
6h ago
